Clinical Trial Update: Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients [EARLY_Phase 1]

View source ↗

Summary

This early-phase 1 trial is evaluating the safety and dystrophin expression of SPOT-mRNA03 in patients with Duchenne muscular dystrophy and is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• SPOT-mRNA03

Snippet

Sponsor: Shanghai Siponuoyin Biotechnology Co Ltd | Conditions: Duchenne Muscular Dystrophy (DMD) | EARLY_Phase 1 | Status: RECRUITING